Sign in
Taking people in United StatesPhase 4

Tests mirabegron and tadalafil for blood sugar control in prediabetes

Tests two drugs against placebo in adults with prediabetes and obesity for 14 weeks.

Key facts

Who runs it
Philip Kern
Where
Lexington, United StatesSee the site
Trial code
Registry title
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
Status
Recruiting
Phase
Phase 4
People taking part
96 people, planned
Started
13 Dec 2021
Expected to end
Jan 2027
Type of study
Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Mirabegron 50 MG
  • Tadalafil 10 MG
  • Placebo
Record updated
31 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with prediabetes and overweight or obesity. It tests mirabegron, tadalafil, or both, compared with a placebo, for 14 weeks.

Age
35 to 65 years
Sex
Women and men can join
Disease stage
Prediabetes: hemoglobin A1C between 5.7 and 6.4, and body mass index between 27 and 45
Earlier treatment
People who take antidiabetic medicines long-term, steroids, daily NSAIDs or anticoagulants cannot join
Biomarker or test result
Hemoglobin A1C between 5.7 and 6.4

Main reasons for not taking part

  • Diabetes
  • Long-term use of any antidiabetic medicines
  • Any unstable medical condition
  • Use of steroids, daily NSAIDs or anticoagulants
  • History of chronic inflammatory conditions

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Hemoglobin A1C between 5.7 and 6.4
  • Body mass index between 27 and 45

Who cannot take part

  • Chronic use of any antidiabetic medications
  • Use of steroids or daily use of NSAIDS
  • Diabetes
  • Any unstable medical condition
  • History of chronic inflammatory conditions
  • Any condition deemed risky by the study physician
  • Use of anticoagulants
  • Contraindications to the use of mirabegron or tadalafil

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 35 and 65 years old?

Where in United States

  • University of KentuckyLexington, United StatesContact: Zach LeichtTaking people

About the trial

What the trial wants to find out

The investigator hypothesizes that treatment with the ß3 agonist mirabegron results in improved glucose metabolism, including a reversal of prediabetes in obese, insulin-resistant human research participants, and this is further improved by combination therapy with tadalafil. The investigator will comprehensively analyze glucose homeostasis in prediabetic patients treated for 14 weeks with mirabegron, tadalafil or both drugs as compared to a placebo.

The 4 groups in the trial

  • Mirabegron (M)Treatment being tested

    Drug will be administered for 12 weeks after baseline procedures.

    Treatment: Mirabegron 50 MG

  • Tadalafil (T)Treatment being tested

    Drug will be administered for 12 weeks after baseline procedures.

    Treatment: Tadalafil 10 MG

  • Mirabegron and Tadalafil (MT)Treatment being tested

    Both drugs will be administered for 12 weeks after baseline procedures.

    Treatment: Mirabegron 50 MG and Tadalafil 10 MG

  • Placebo (P)Placebo, for comparison

    Treatment: Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
Plain-language title
Tests mirabegron and tadalafil for blood sugar control in prediabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT05051436, who can take part
Record updated
31 August 2026